Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Shandong New Time Pharmaceutical Co., Ltd.

Home Clinical Trial Sponsors and OrganizationsShandong New Time Pharmaceutical Co., Ltd.

Shandong New Time Pharmaceutical Co., Ltd.

No. 1, North Outer Ring Road, Feixian, Linyi, Shandong, China

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

34

10 active

Approvals

11

Total approvals

Agencies

2

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

13

38.2%

Phase 1

9

26.5%

Phase 3

6

17.6%

Not Applicable

4

11.8%

Phase 4

2

5.9%

Trial Status Distribution

Completed

7

20.6%

Enrolling By Invitation

2

5.9%

Not yet recruiting

8

23.5%

Recruiting

8

23.5%

Unknown

9

26.5%

Clinical Trials

Trials sponsored by this organization (34)

A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)

Jul 2026402 participants

Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors

Not yet recruiting

Jun 2026294 participants

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Jan 2026261 participants

F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus

Oct 202564 participants

Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

Not yet recruiting

Aug 2025496 participants

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Jul 202590 participants

A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents

Enrolling By Invitation

Feb 2025342 participants

Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding

Not yet recruiting

Feb 2025150 participants

Page 1 of 5

Approvals

Approvals by Agency

FDA

Food and Drug Administration

10

Approvals

NPRA

National Pharmaceutical Regulatory Agency

1

Approvals

Recent Approvals

Milrinone Lunan 1 mg/ml Solution for Injection

Rocuronium Bromide

Milrinone Lactate

Milrinone Lactate

Rosuvastatin Calcium

Rosuvastatin Calcium

Isosorbide Mononitrate

News

No news articles found

On this page

Overview
Clinical Trials34
Approvals11
News

Back to Organizations